Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Research Article

A Retrospective Cohort Study of Histology-Proven Neuroendocrine Neoplasms in the Italian Area of Udine

Author(s): Francesca Valent*, Annarita Tullio, Elda Kara, Claudia Cipri, Silvia M. Sciannimanico, Fabio Vescini and Franco Grimaldi

Volume 21 , Issue 3 , 2021

Published on: 13 July, 2020

Page: [448 - 457] Pages: 10

DOI: 10.2174/1871530320666200713093533

Price: $65

Abstract

Aims: The aim of this study was to investigate the epidemiology of histology-proven Neuroendocrine neoplasms (NENs) in an Italian area.

Background: NENs are a rare and poorly known disease and the global incidence and prevalence appear to be increasing over the past decades.

Objective: The objectives of this study were to estimate the incidence and trends of NENs in a 250,000-inhabitant area in the North-East of Italy in the 1998-2018 period and to compare them with international data.

Methods: This retrospective cohort study was based on the analysis of anonymous health administrative databases, linked with each other at individual patient level through an anonymous stochastic key. NENs were identified from the anatomical pathology database.

The standardized incidence rate (2010ESP and US2000) ± 95% CI per 100,000 were calculated, both annually and globally, for the whole period. Incidence was also calculated for specific anatomical sites and by gender.

Trends for the considered periods and sites were summarized through the annual percent change (APC) and average increase (cases per 100,000 per year).

Results: In the 1998-2018 period, the standardized incidence rate of NENs in the area of Udine was 2.49 (APC 3.33). A total of 162 cases were observed (51.2% males). Differences in incidence and trend were observed between sexes. The obtained results were consistent with those reported in other countries, confirming a significant and steady increase in NENs incidence in the last twenty years.

Conclusion: This study provides new epidemiological data on NENs in Italy. The observed sex differences deserve further investigations.

Keywords: Neuroendocrine tumors, incidence, rare tumors, Italy, epidemiology, tumors.

Graphical Abstract
[1]
Inzani, F.; Petrone, G.; Fadda, G.; Rindi, G. Cyto-histology in NET: what is necessary today and what is the future? Rev. Endocr. Metab. Disord., 2017, 18(4), 381-391.
[http://dx.doi.org/10.1007/s11154-017-9428-x] [PMID: 28871510]
[2]
Rindi, G.; Klimstra, D.S.; Abedi-Ardekani, B.; Asa, S.L.; Bosman, F.T.; Brambilla, E.; Busam, K.J.; de Krijger, R.R.; Dietel, M.; El-Naggar, A.K.; Fernandez-Cuesta, L.; Klöppel, G.; McCluggage, W.G.; Moch, H.; Ohgaki, H.; Rakha, E.A.; Reed, N.S.; Rous, B.A.; Sasano, H.; Scarpa, A.; Scoazec, J.Y.; Travis, W.D.; Tallini, G.; Trouillas, J.; van Krieken, J.H.; Cree, I.A. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol., 2018, 31(12), 1770-1786.
[http://dx.doi.org/10.1038/s41379-018-0110-y] [PMID: 30140036]
[3]
Pearse, A.G. The diffuse neuroendocrine system and the apud concept: related “endocrine” peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med. Biol., 1977, 55(3), 115-125.
[PMID: 330966]
[4]
Van Cutsem, E. ESMO Epidemiology Classification and Clinical Presentation of NETs a European Perspective - NeuroEndocrine Tumors: Diagnostic and therapeutic challenges: introduction, 2018. Available at: https://www.esmo.org/content/download/8584/174877/file/ESMO-Epidemiology-classification-and-clinical-presentation-of-NETs-A-European_Perspective.pdf
[5]
Caldarella, A.; Crocetti, E.; Paci, E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol. Oncol. Res., 2011, 17(3), 759-763.
[http://dx.doi.org/10.1007/s12253-011-9382-y] [PMID: 21476126]
[6]
Associazione Italiana di Oncologia Medica – Linee Guida Neoplasie Neuroendocrine Gastroenteropancreatiche – Edizione. 2013 Available at:.http://media.aiom.it/userfiles/files/doc/LG/2013_LG_AIOM_ Neuroendocrini_v.9_9.10.13.pdf
[7]
Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; Evans, D.B. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26(18), 3063-3072.
[http://dx.doi.org/10.1200/JCO.2007.15.4377] [PMID: 18565894]
[8]
Hauso, O.; Gustafsson, B.I.; Kidd, M.; Waldum, H.L.; Drozdov, I.; Chan, A.K.; Modlin, I.M. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer, 2008, 113(10), 2655-2664.
[http://dx.doi.org/10.1002/cncr.23883] [PMID: 18853416]
[9]
Associazione Italiana di Oncologia Medica – Linee Guida Neoplasie Neuroendocrine – Edizione. 2018 Available at:.https://www.aiom.it/wp content/uploads/2018/11/2018_LG_AIOM_NEN_algoritmi.pdf
[10]
Hwang, T. 8th Annual ENETS Conference, March 9-11, 2011Lisbon, Portugal
[11]
Rindi, G.; Arnold, R.; Bosman, F.T. Nomenclature and classification of neuroendocrine neoplasms of the digestive system.WHO Classification of Tumours of the Digestive System, 4th; WHO Press, Lyon 2010, Editor: Bosman FT, Carneiro F, Hruban RH, Theise , 2010.
[12]
Leoncini, E.; Boffetta, P.; Shafir, M.; Aleksovska, K.; Boccia, S.; Rindi, G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine, 2017, 58(2), 368-379.
[http://dx.doi.org/10.1007/s12020-017-1273-x] [PMID: 28303513]
[13]
Hallet, J.; Law, C.H.; Cukier, M.; Saskin, R.; Liu, N.; Singh, S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer, 2015, 121(4), 589-597.
[http://dx.doi.org/10.1002/cncr.29099] [PMID: 25312765]
[14]
Cao, L.L.; Lu, J.; Lin, J.X.; Zheng, C.H.; Li, P.; Xie, J.W.; Wang, J.B.; Chen, Q.Y.; Lin, M.; Tu, R.H.; Huang, C.M. Incidence and survival trends for gastric neuroendocrine neoplasms: an analysis of 3523 patients in the SEER database. Eur. J. Surg. Oncol., 2018, 44(10), 1628-1633.
[http://dx.doi.org/10.1016/j.ejso.2018.01.082] [PMID: 29983275]
[15]
Lepage, C.; Bouvier, A.M.; Manfredi, S.; Dancourt, V.; Faivre, J. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am. J. Gastroenterol., 2006, 101(12), 2826-2832.
[http://dx.doi.org/10.1111/j.1572-0241.2006.00854.x] [PMID: 17026561]
[16]
Korse, C.M.; Taal, B.G.; van Velthuysen, M.L.; Visser, O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur. J. Cancer, 2013, 49(8), 1975-1983.
[http://dx.doi.org/10.1016/j.ejca.2012.12.022] [PMID: 23352435]
[17]
Scherübl, H.; Streller, B.; Stabenow, R.; Herbst, H.; Höpfner, M.; Schwertner, C.; Steinberg, J.; Eick, J.; Ring, W.; Tiwari, K.; Zappe, S.M. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J. Gastroenterol., 2013, 19(47), 9012-9019.
[http://dx.doi.org/10.3748/wjg.v19.i47.9012] [PMID: 24379626]
[18]
Ellis, L.; Shale, M.J.; Coleman, M.P. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am. J. Gastroenterol., 2010, 105(12), 2563-2569.
[http://dx.doi.org/10.1038/ajg.2010.341] [PMID: 20823835]
[19]
Landerholm, K.; Falkmer, S.; Järhult, J. Epidemiology of small bowel carcinoids in a defined population. World J. Surg., 2010, 34(7), 1500-1505.
[http://dx.doi.org/10.1007/s00268-010-0519-z] [PMID: 20237925]
[20]
Skuladottir, H.; Hirsch, F.R.; Hansen, H.H.; Olsen, J.H. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer, 2002, 37(2), 127-135.
[http://dx.doi.org/10.1016/S0169-5002(02)00080-6] [PMID: 12140134]
[21]
Levi, F.; Te, V.C.; Randimbison, L.; Rindi, G.; La Vecchia, C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br. J. Cancer, 2000, 83(7), 952-955.
[http://dx.doi.org/10.1054/bjoc.2000.1394] [PMID: 10970700]
[22]
Tsai, H.J.; Wu, C.C.; Tsai, C.R.; Lin, S.F.; Chen, L.T.; Chang, J.S. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One, 2013, 8(4)e62487
[http://dx.doi.org/10.1371/journal.pone.0062487] [PMID: 23614051]
[23]
Surveillance, E.; Results, E. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, www.seer.cancer.gov2015.
[24]
Valent, F. Uso del sistema informativo sanitario del Friuli Venezia Giulia per la costruzione di un registro regionale dei soggetti con diabete mellito. Available at: , http://www.epicentro.iss.it/ben/2016/ottobre/2 (Accessed 2019).
[25]
Surveillance, E.; Results, E. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, www.seer.cancer.gov (Accessed 2019).
[26]
Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.3.5, seer.cancer.gov/seerstat
[27]
Kim, H.J.; Fay, M.P.; Feuer, E.J.; Midthune, D.N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med., 2000, 19(3), 335-351.
[http://dx.doi.org/10.1002/(SICI)1097-0258(20000215)19:3<335:AID-SIM336>3.0.CO;2-Z] [PMID: 10649300]
[28]
Jianu, C.S.; Fossmark, R.; Viset, T.; Qvigstad, G.; Sørdal, O.; Mårvik, R.; Waldum, H.L. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment. Pharmacol. Ther., 2012, 36(7), 644-649.
[http://dx.doi.org/10.1111/apt.12012] [PMID: 22861200]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy